These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 29332569)

  • 1. Cancer Treatment with Liposomes Based Drugs and Genes Co-delivery Systems.
    Zhang C; Zhang S; Zhi D; Cui J
    Curr Med Chem; 2018; 25(28):3319-3332. PubMed ID: 29332569
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Polymers in the Co-delivery of siRNA and Anticancer Drugs for the Treatment of Drug-resistant Cancers.
    Sun H; Yarovoy I; Capeling M; Cheng C
    Top Curr Chem (Cham); 2017 Apr; 375(2):24. PubMed ID: 28176270
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Drug and gene co-delivery systems for cancer treatment.
    Yang Z; Gao D; Cao Z; Zhang C; Cheng D; Liu J; Shuai X
    Biomater Sci; 2015 Jul; 3(7):1035-49. PubMed ID: 26221938
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of integrated cancer nanomedicine in overcoming drug resistance.
    Iyer AK; Singh A; Ganta S; Amiji MM
    Adv Drug Deliv Rev; 2013 Nov; 65(13-14):1784-802. PubMed ID: 23880506
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The importance of co-delivery of nanoparticle-siRNA and anticancer agents in cancer therapy.
    Khelghati N; Soleimanpour Mokhtarvand J; Mir M; Alemi F; Asemi Z; Sadeghpour A; Maleki M; Samadi Kafil H; Jadidi-Niaragh F; Majidinia M; Yousefi B
    Chem Biol Drug Des; 2021 Apr; 97(4):997-1015. PubMed ID: 33458952
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Co-delivery Systems of Multiple Drugs Using Nanotechnology for Future Cancer Therapy.
    Fumoto S; Nishida K
    Chem Pharm Bull (Tokyo); 2020; 68(7):603-612. PubMed ID: 32611997
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy.
    Pérez-Herrero E; Fernández-Medarde A
    Eur J Pharm Biopharm; 2015 Jun; 93():52-79. PubMed ID: 25813885
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reversal of multidrug resistance by co-delivery of paclitaxel and lonidamine using a TPGS and hyaluronic acid dual-functionalized liposome for cancer treatment.
    Assanhou AG; Li W; Zhang L; Xue L; Kong L; Sun H; Mo R; Zhang C
    Biomaterials; 2015 Dec; 73():284-95. PubMed ID: 26426537
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The use of liposomal anticancer agents to determine the roles of drug pharmacodistribution and P-glycoprotein (PGP) blockade in overcoming multidrug resistance (MDR).
    Krishna R; Mayer LD
    Anticancer Res; 1999; 19(4B):2885-91. PubMed ID: 10652569
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Trilysinoyl oleylamide-based cationic liposomes for systemic co-delivery of siRNA and an anticancer drug.
    Shim G; Han SE; Yu YH; Lee S; Lee HY; Kim K; Kwon IC; Park TG; Kim YB; Choi YS; Kim CW; Oh YK
    J Control Release; 2011 Oct; 155(1):60-6. PubMed ID: 20971142
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of targeting lonidamine liposomes that circumvent drug-resistant cancer by acting on mitochondrial signaling pathways.
    Li N; Zhang CX; Wang XX; Zhang L; Ma X; Zhou J; Ju RJ; Li XY; Zhao WY; Lu WL
    Biomaterials; 2013 Apr; 34(13):3366-80. PubMed ID: 23410681
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Co-delivery of chemosensitizing siRNA and an anticancer agent via multiple monocomplexation-induced hydrophobic association.
    Lee E; Oh C; Kim IS; Kwon IC; Kim S
    J Control Release; 2015 Jul; 210():105-14. PubMed ID: 25979325
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recent advances in mechanism-based chemotherapy drug-siRNA pairs in co-delivery systems for cancer: A review.
    Wang M; Wang J; Li B; Meng L; Tian Z
    Colloids Surf B Biointerfaces; 2017 Sep; 157():297-308. PubMed ID: 28601758
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recent advances in co-delivery nanosystems for synergistic action in cancer treatment.
    Carvalho BG; Vit FF; Carvalho HF; Han SW; de la Torre LG
    J Mater Chem B; 2021 Feb; 9(5):1208-1237. PubMed ID: 33393582
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Integrated hollow mesoporous silica nanoparticles for target drug/siRNA co-delivery.
    Ma X; Zhao Y; Ng KW; Zhao Y
    Chemistry; 2013 Nov; 19(46):15593-603. PubMed ID: 24123533
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Opportunities and challenges for co-delivery nanomedicines based on combination of phytochemicals with chemotherapeutic drugs in cancer treatment.
    Gao Q; Feng J; Liu W; Wen C; Wu Y; Liao Q; Zou L; Sui X; Xie T; Zhang J; Hu Y
    Adv Drug Deliv Rev; 2022 Sep; 188():114445. PubMed ID: 35820601
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enhanced Cytotoxicity of Folic Acid-Targeted Liposomes Co-Loaded with C6 Ceramide and Doxorubicin: In Vitro Evaluation on HeLa, A2780-ADR, and H69-AR Cells.
    Sriraman SK; Pan J; Sarisozen C; Luther E; Torchilin V
    Mol Pharm; 2016 Feb; 13(2):428-37. PubMed ID: 26702994
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Liposome-based co-delivery of siRNA and docetaxel for the synergistic treatment of lung cancer.
    Qu MH; Zeng RF; Fang S; Dai QS; Li HP; Long JT
    Int J Pharm; 2014 Oct; 474(1-2):112-22. PubMed ID: 25138252
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Surface Functionalization and Targeting Strategies of Liposomes in Solid Tumor Therapy: A Review.
    Riaz MK; Riaz MA; Zhang X; Lin C; Wong KH; Chen X; Zhang G; Lu A; Yang Z
    Int J Mol Sci; 2018 Jan; 19(1):. PubMed ID: 29315231
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Liposomes Co- encapsulating Anticancer Drugs in Synergistic Ratios as an Approach to Promote Increased Efficacy and Greater Safety.
    Franco MS; Oliveira MC
    Anticancer Agents Med Chem; 2019; 19(1):17-28. PubMed ID: 29692263
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.